Bio/Pharma Business

Growth in Cell and Gene Therapy Market

October 02, 2022

Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.

Novo Nordisk Inks $700 Million Deal with Ventus Therapeutics

September 30, 2022

Novo Nordisk will pay up to $700 million for the exclusive rights to develop and commercialize candidates from Ventus Therapeutics NLRP3 inhibitor portfolio.

Actylis Debuts as an Integrated Global Specialty Ingredients Manufacturing and Sourcing Provider

September 28, 2022

Actylis combines Aceto and its 10 acquired specialists into a singular global brand.

CytoReason Announces Expanded Collaboration Deal with Pfizer

September 20, 2022

CytoReason has announced an expanded collaboration deal with Pfizer to deliver AI for drug discovery and development.

Novo Nordisk and Microsoft Collaborate to Accelerate Drug Discovery and Development

September 19, 2022

Novo Nordisk and Microsoft are collaborating to accelerate drug discovery and development using big data and artificial intelligence.

Ensysce Biosciences and Quotient Sciences Announce Partnership

September 19, 2022

Ensysce Biosciences and Quotient Sciences are partnering to develop and test Ensysce’s novel opioid designed to prevent abuse and overdose.

Advanced Biopharma Manufacturing Key to White House Cancer Moonshot

September 16, 2022

The White House hopes to expand US modern biotech manufacturing and reduce reliance on foreign sources of bioindustrial materials.

Emergence Therapeutics to License Synaffix ADC Technology Platform in Deal Worth Up to $360 Million

September 14, 2022

Emergence Therapeutics will work with Synaffix’s ADC technology platform to develop multiple ADCs against undisclosed targets.

Salipro Biotech Obtains Patents in US and China for Direct Extraction of Membrane Proteins and Library Generation

September 09, 2022

Salipro has been granted patents in the United States and China for its proprietary technology to enable the development of therapeutics against challenging drug targets.

Avance Clinical Acquires C3 Research Associates

September 09, 2022

Avance Clinical’s acquisition of C3 Research Associates expands its CRO services to North America.